StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $0.47 on Monday. Evoke Pharma has a 1-year low of $0.41 and a 1-year high of $2.06. The company has a 50-day moving average of $0.52 and a 200 day moving average of $0.79. The firm has a market cap of $4.04 million, a PE ratio of -0.26 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter. The firm had revenue of $1.74 million during the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- What is the FTSE 100 index?
- What is a Short Call Butterfly Spread? Explanation with Examples
- Dividend Capture Strategy: What You Need to Know
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- What is Put Option Volume?
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
